Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026
Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026
Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Fineline Cube Mar 18, 2026
Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Fineline Cube Mar 18, 2026
Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Fineline Cube Mar 18, 2026
Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026
Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026
Company Drug

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

Fineline Cube Mar 18, 2026
Company Drug

Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...

Company Drug

Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014

Fineline Cube Oct 10, 2022

China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...

Company Deals

Fujian Cosunter to Acquire UDCA Capsules Technology from Ruitailai

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a...

Company Drug

Fujian Cosunter Doses First Patient in Phase I Study of COVID-19 Drug GST-HG171

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the first patient has...

Company Drug

Salubris Pharmaceuticals’ First-in-Class Anti-Tumor Drug SAL008 Accepted by NMPA

Fineline Cube Oct 10, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that a clinical trial filing...

Company Drug

Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer

Fineline Cube Oct 10, 2022

Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...

Policy / Regulatory

CDE Releases 63rd Batch of Chemical Generic Reference Preparations

Fineline Cube Oct 10, 2022

The Center for Drug Evaluation (CDE) has released the 63rd batch of chemical generic reference...

Policy / Regulatory

Jiangsu Launches Sunshine Procurement Platform for Drugs and Medical Consumables

Fineline Cube Oct 10, 2022

Jiangsu province has launched its drugs and medical consumables sunshine procurement services website, providing a...

Company Drug

Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...

Company Deals

Convalife and Jointown Partner for Global Drug Development and Commercialization

Fineline Cube Oct 9, 2022

Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...

Company Drug

Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers

Fineline Cube Oct 9, 2022

Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...

Company Deals

VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D

Fineline Cube Oct 9, 2022

Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital...

Company Policy / Regulatory

WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions

Fineline Cube Oct 9, 2022

The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...

Company Policy / Regulatory

India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole

Fineline Cube Oct 9, 2022

The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...

Policy / Regulatory

China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval

Fineline Cube Oct 9, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...

Company Drug

Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection

Fineline Cube Oct 9, 2022

China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...

Company Drug

Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC

Fineline Cube Oct 9, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...

Company Drug

Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes

Fineline Cube Oct 9, 2022

China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...

Company Drug Medical Device

Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng

Fineline Cube Oct 9, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...

Company Deals

Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch

Fineline Cube Oct 9, 2022

China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...

Posts pagination

1 … 587 588 589 … 636

Recent updates

  • Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder
  • Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders
  • FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment
  • Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development
  • Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.